Abstract
Anaplastic lymphoma kinase (ALK)-fusion sarcomas are rare part of the emerging theoretically targetable tyrosine kinase RAS::MAPK pathway fusion myopericytic-ovoid sarcomas. We report our clinicopathologic and treatment experience with an ALK fusion sarcoma. A novel ELKS/RAB6-interacting/CAST family member 1-unaligned ALK fusion infiltrative nonmetastatic low-grade sarcoma of the right hand of a 15-month-old male was treated with crizotinib, an ALK tyrosine kinase inhibitor as oral monotherapy, inducing complete radiographic and clinical resolution by 10 months and sustained response now over 12 months after elective discontinuation. Crizotinib can successfully be used to treat unresectable novel ALK fusion sarcomas.
| Original language | English |
|---|---|
| Pages (from-to) | E184-E187 |
| Journal | Journal of Pediatric Hematology/Oncology |
| Volume | 46 |
| Issue number | 2 |
| DOIs | |
| State | Published - 1 Mar 2024 |
Keywords
- Anaplastic Lymphoma Kinase/genetics
- Child
- Crizotinib/therapeutic use
- Humans
- Infant
- Lung Neoplasms/pathology
- Male
- Protein Kinase Inhibitors/therapeutic use
- Protein-Tyrosine Kinases/therapeutic use
- Sarcoma/drug therapy
- Soft Tissue Neoplasms/drug therapy
Fingerprint
Dive into the research topics of 'Successful Crizotinib-Targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver